spacer
home > white papers > Antibody Internalization: Advanced Flow Cytometry and Live-Cell Analysis Give Rich Insights During Antibody Profiling - Sartorius Group
WHITE PAPERS
logo_Sartorius_.jpg

Sartorius Group

phone +49.551.308.0
email info@sartorius.com
web http://www.sartorius.com
email Sartorius Corporation, Otto-Brenner-Straße 20, 37079 Goettingen, Germany

Antibody Internalization: Advanced Flow Cytometry and Live-Cell Analysis Give Rich Insights During Antibody Profiling

The natural characteristics of antibodies, such as high binding affinity, specificity to a wide variety of targets, and good stability, make them ideal therapeutic candidates for many diseases. Monoclonal antibodies (mAbs), in particular, deliver promising therapeutic results in several different disease areas, such as autoimmunity, oncology, and chronic inflammation. Researchers’ abilities to improve the breadth of antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody design techniques create the need for new screening methods so that lead candidates can be quickly and effectively identified as early in the development process as possible.
Antibody Internalization: Advanced Flow Cytometry and Live-Cell Analysis Give Rich Insights During Antibody Profiling
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Specialized expertise that gives you an inside edge

Tap into the knowledge of specialists with decades of experience identifying and solving difficult challenges. From technical obstacles such as siliconization and lyophilization to strategic issues such as life cycle planning, Vetter’s integrated team approach brings together the right experts for your compound’s precise requirements.
More info >>


White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>


Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement